SPECTRUM PHARMACEUTICALS INC Form 8-K August 09, 2005 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES AND EXCHANGE ACT OF 1934 August 9, 2005 (August 9, 2005) Date of Report (Date of earliest event reported)

SPECTRUM PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware (State or other Jurisdiction

of Incorporation)

Table of Contents

000-28782 (Commission File Number) **93-0979187** (IRS Employer Identification Number)

92618

(Zip Code)

157 Technology Drive Irvine, California (Address of principal executive offices)

(949) 788-6700

(Registrant s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: SPECTRUM PHARMACEUTICALS INC - Form 8-K

TABLE OF CONTENTS

Item 2.02. Results of Operations and Financial Condition. Item 9.01. Financial Statements and Exhibits. SIGNATURES EXHIBIT 99.1

Table of Contents

Item 2.02. Results of Operations and Financial Condition.

On August 9, 2005, we issued a press release, which sets forth our results of operations for the quarter ended June 30, 2005. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. **Item 9.01. Financial Statements and Exhibits.**

(c) Exhibits

Exhibits: Description of Document

99.1 Press Release dated August 9, 2005.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 9, 2005

SPECTRUM PHARMACEUTICALS, INC.

By: /s/ Rajesh C. ShrotriyaName: Rajesh C. ShrotriyaTitle: Chairman, Chief Executive Officer and President

Table of Contents

EXHIBIT INDEX

99.1 Press Release dated August 9, 2005.